Recombinant multi-species EIF2S1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine EIF2S1 protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The translation initiation factor EIF2 catalyzes the first regulated step of protein synthesis initiation, promoting the binding of the initiator tRNA to 40S ribosomal subunits. Binding occurs as a ternary complex of methionyl-tRNA, EIF2, and GTP. EIF2 is composed of 3 nonidentical subunits, the 36-kD EIF2-alpha subunit (EIF2S1), the 38-kD EIF2-beta subunit (EIF2S2; MIM 603908), and the 52-kD EIF2-gamma subunit (EIF2S3; MIM 300161). The rate of formation of the ternary complex is modulated by the phosphorylation state of EIF2-alpha (Ernst et al., 1987 [PubMed 2948954]).[supplied by OMIM, Feb 2010]
The Alternative Names of target: 0910001O23Rik,2410026C18Rik,35kDa,EIF-2,EIF-2A,EIF-2alpha,EIF2,EIF2A,EIF2S1,Eif2a,Eif2s1,Eukaryotic translation initiation factor 2 subunit 1,Eukaryotic translation initiation factor 2 subunit alpha (eIF-2-alpha,eIF-2A,eIF-2alpha,eIF2-alpha),eIF2alpha

Target products collectionGo to EIF2S1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-IP6296-Ag-1/ GM-Tg-hg-IP6296-Ag-2 Human EIF2S1 protein Human
GM-Tg-rg-IP6296-Ag-1/ GM-Tg-rg-IP6296-Ag-2 Rat EIF2S1 protein Rat
GM-Tg-mg-IP6296-Ag-1/ GM-Tg-mg-IP6296-Ag-2 Mouse EIF2S1 protein Mouse
GM-Tg-cynog-IP6296-Ag-1/ GM-Tg-cynog-IP6296-Ag-2 Cynomolgus/Rhesus macaque EIF2S1 protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-IP6296-Ag-1/ GM-Tg-felg-IP6296-Ag-2 Feline EIF2S1 protein Feline
GM-Tg-cang-IP6296-Ag-1/ GM-Tg-cang-IP6296-Ag-2 Canine EIF2S1 protein Canine
GM-Tg-bovg-IP6296-Ag-1/ GM-Tg-bovg-IP6296-Ag-2 Bovine EIF2S1 protein Bovine
GM-Tg-equg-IP6296-Ag-1/ GM-Tg-equg-IP6296-Ag-2 Equine EIF2S1 protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-IP6296-Ag-1/ GM-Tg-hg-IP6296-Ag-2; GM-Tg-rg-IP6296-Ag-1/ GM-Tg-rg-IP6296-Ag-2;
GM-Tg-mg-IP6296-Ag-1/ GM-Tg-mg-IP6296-Ag-2; GM-Tg-cynog-IP6296-Ag-1/ GM-Tg-cynog-IP6296-Ag-2;
GM-Tg-felg-IP6296-Ag-1/ GM-Tg-felg-IP6296-Ag-2; GM-Tg-cang-IP6296-Ag-1/ GM-Tg-cang-IP6296-Ag-2;
GM-Tg-bovg-IP6296-Ag-1/ GM-Tg-bovg-IP6296-Ag-2; GM-Tg-equg-IP6296-Ag-1/ GM-Tg-equg-IP6296-Ag-2
Products Name EIF2S1 protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name EIF2S1
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine EIF2S1 protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.